Xspray Pharma’s Nomination Committee for the Annual General Meeting 2025
Kurs
+1,97%
Likviditet
3,02 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2025-05-13 | - | Årsstämma |
| 2025-05-07 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-02 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Extra Bolagsstämma 2023 |
| 2023-05-16 | - | Årsstämma |
| 2023-05-05 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-10-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-06 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2021-05-20 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-26 | - | Extra Bolagsstämma 2020 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Årsstämma |
| 2019-05-17 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-28 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2018-05-14 | - | Årsstämma |
| 2018-05-14 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Extra Bolagsstämma 2017 |
| 2018-02-19 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting, May 13, 2025.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 21 May 2024, consists of:
- Thomas Eldered, appointed by Flerie AB, Chairman of the Nomination Committee
- Johan Gyllenswärd, appointed by Ribbskottet AB
- Mattias Klintemar, appointed by The Foundation for Baltic and East European Studies
- Johan Wadell, appointed by AP2
- Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
The Nomination Committee shall, before the Annual General Meeting on May 13, 2025, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.
Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting, can do so via e-mail to generalmeeting@xspray.com before March 25, 2025.
For further information about the Nomination Committee, please contact:
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
Email: anders.ekblom@xspray.com
For further information, please contact:
Kerstin Hasselgren
Senior Advisor & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 70 311 16 83
E-mail: kerstin.hasselgren@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.